A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
Clinical trial NCT00875979 · COMPLETED
Trial details
- NCT number
- NCT00875979
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-05-01
- Primary completion
- 2011-08-01
- Enrollment
- 67
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.